Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19
oleh: Wenping Gong, Yinping Liu, Yong Xue, Li Zhuang, Li Zhuang
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2023-05-01 |
Deskripsi
Subjek
Bacillus Calmette-Guérin (BCG); tuberculosis (TB); COVID-19; clinical trial; latent tuberculosis infection (LTBI)